The 12 most recent market catalysts affecting $REGN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 10, 2026
Corporate Catalyst
Bullish
Impact 55
HSBC Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $920
HSBC analyst Rajesh Kumar has maintained a 'Buy' rating on Regeneron Pharmaceuticals (REGN) and significantly raised its price target from $800 to $920. This analyst action signals…
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 75
Regeneron Secures FDA Approval For Ultra-Rare Bone Disorder Drug
Regeneron Pharmaceuticals (REGN) has secured FDA approval for Pasatru (garetosmab-grts), a drug targeting fibrodysplasia ossificans progressiva (FOP), an ultra-rare bone disorder. …
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 85
Regeneron Pharmaceuticals Granted FDA Approval For Pasatru To Lower Formation Of New Heterotopic Ossification Lesions And Clinician-Assessed Flare-Ups In Adults With Fibrodysplasia Ossificans Progressiva
Regeneron Pharmaceuticals received FDA approval for Pasatru, a drug designed to treat fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder. This approval is a signi…
Aug 6, 2026
Corporate Catalyst
Neutral
Impact 65
LibtayoReceives Health Canada Approval for Adjuvant Treatment Of High-Risk Cutaneous Squamous Cell Carcinoma
The filing discloses that Libtayo (cemiplimab), a drug developed by Regeneron and Sanofi, has received Health Canada approval for the adjuvant treatment of high-risk cutaneous squa…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1030
Guggenheim analyst Brad Canino maintained a 'Buy' rating on Regeneron Pharmaceuticals (REGN) and raised the price target from $1000 to $1030. This action signals continued bullish …
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 75
Regeneron Pharmaceuticals shares are trading higher after multiple analysts raised their respective price targets on the stock.
This headline signals a strong positive sentiment for Regeneron Pharmaceuticals, driven by professional analysts. Increased price targets often lead to increased investor confidenc…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $737
RBC Capital analyst Brian Abrahams reiterated a 'Sector Perform' rating on Regeneron Pharmaceuticals (REGN) but raised the price target from $696 to $737. This action suggests that…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
Cantor Fitzgerald Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $795
Cantor Fitzgerald analyst Carter Gould maintained an 'Overweight' rating on Regeneron Pharmaceuticals and raised the price target from $750 to $795. This action signals continued c…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $772
Truist Securities analyst Gregory Renza maintained a 'Buy' rating on Regeneron Pharmaceuticals and raised the price target from $769 to $772. This action signals continued confiden…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 75
Regeneron Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.
Regeneron's strong Q2 earnings are a direct corporate catalyst, indicating robust company-specific performance. This positive news primarily impacts REGN shares, driving them highe…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 92
Regeneron Pharmaceuticals Q2 Adj. EPS $14.29 Beats $10.26 Estimate, Sales $4.291B Beat $3.816B Estimate
Regeneron Pharmaceuticals (REGN) announced Q2 adjusted EPS of $14.29, significantly exceeding the analyst consensus of $10.26, and sales of $4.291 billion, beating the $3.816 billi…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1000
Guggenheim analyst Brad Canino maintained a 'Buy' rating on Regeneron Pharmaceuticals (REGN) and raised the price target from $995 to $1000. This action signals continued analyst c…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.